Preferred Label : iloprost;
MeSH definition : An eicosanoid, derived from the cyclooxygenase pathway of arachidonic acid metabolism.
It is a stable and synthetic analog of EPOPROSTENOL, but with a longer half-life than
the parent compound. Its actions are similar to prostacyclin. Iloprost produces vasodilation
and inhibits platelet aggregation.; A stable analog of EPOPROSTENOL that is a PLATELET AGGREGATION INHIBITOR; VASODILATOR,
and has cytoprotective properties.;
MeSH synonym : ciloprost;
CISMeF synonym : CoTherix brand of iloprost;
MeSH hyponym : ventavis; ZK-36374; ZK 36374; ZK36374;
MeSH CAS label : pentanoic acid, 5-(hexahydro-5-hydroxy-4-(3-hydroxy-4-methyl-1-octen-6-ynyl)-2(1H)-pentalenylidene)-;
MeSH Related Number : 78919-13-8 (Iloprost);
Registry Number MeSH : 78919-13-8;
Wikipedia link : https://en.wikipedia.org/wiki/Iloprost;
Is substance : O;
UNII : JED5K35YGL;
InChIKey : HIFJCPQKFCZDDL-ACWOEMLNSA-N;
Origin ID : D016285;
UMLS CUI : C0079594;
ATC code(s)
Allowable qualifiers
Currated CISMeF NLP mapping
Manual BTNT mappings - CISMeF
Pharmacological action(s)
Record concept(s)
Related MeSH Supplementary Concept(s)
Semantic type(s)
UMLS correspondences (same concept)
Validated automatic mappings to BTNT
An eicosanoid, derived from the cyclooxygenase pathway of arachidonic acid metabolism.
It is a stable and synthetic analog of EPOPROSTENOL, but with a longer half-life than
the parent compound. Its actions are similar to prostacyclin. Iloprost produces vasodilation
and inhibits platelet aggregation.
A stable analog of EPOPROSTENOL that is a PLATELET AGGREGATION INHIBITOR; VASODILATOR,
and has cytoprotective properties.
https://www.has-sante.fr/jcms/p_3146602/fr/iloprost-teva
2020
false
false
false
France
infusions, intravenous
drugs, generic
evaluation of the transparency committee
iloprost
---
https://www.has-sante.fr/jcms/p_3135580/fr/ilomedine
2019
false
false
false
France
French
iloprost
treatment outcome
insurance, health, reimbursement
infusions, intravenous
raynaud disease
iloprost
ischemia
lower extremity
chronic disease
vasodilator agents
evaluation of the transparency committee
---
http://www.has-sante.fr/portail/jcms/c_2013186/fr/ventavis
2015
true
France
French
insurance, health, reimbursement
administration, inhalation
hypertension, pulmonary
vasodilator agents
iloprost
treatment outcome
evaluation of the transparency committee
---
https://www.ema.europa.eu/medicines/human/EPAR/Ventavis
2012
United Kingdom
French
English
syndication feed
hypertension, pulmonary
vasodilator agents
iloprost
treatment outcome
drug evaluation
orphan drug production
iloprost
package leaflet
drug evaluation
summary of product characteristics
---
http://www.has-sante.fr/portail/upload/docs/application/pdf/2011-05/synthese_davis_reevaluation_htap_2011-05-12_12-18-35_386.pdf
http://www.has-sante.fr/portail/jcms/c_1053751/medicaments-de-lhypertension-arterielle-pulmonaire-idiopathique-ou-associee-a-une-connectivite
2011
false
France
French
evaluation of the transparency committee
guidelines for drug use
Sildenafil Citrate
Tadalafil
hypertension, pulmonary
collagen diseases
epoprostenol
antihypertensive agents
sulfonamides
treprostinil
epoprostenol
phosphodiesterase 5 inhibitors
iloprost
receptors, endothelin
ambrisentan
phenylpropionates
DERMATITIS
survival analysis
Antihypertensives for pulmonary arterial hypertension
treatment outcome
pyridazines
Bosentan
---
http://www.has-sante.fr/portail/jcms/c_1024129/ventavis
http://www.has-sante.fr/portail/jcms/c_1024280/ventavis-ct-6292
2011
France
French
administration, inhalation
hypertension, pulmonary
vasodilator agents
iloprost
treatment outcome
orphan drug production
evaluation of the transparency committee
---
http://www.cochrane.org/fr/CD000953
2009
false
true
false
United Kingdom
France
treatment outcome
review of literature
french abstract
scleroderma, systemic
iloprost
raynaud disease
---
http://www.has-sante.fr/portail/display.jsp?id=c_245037
2005
France
French
iloprost
vasodilator agents
hypertension, pulmonary
orphan drug production
administration, inhalation
evaluation of the transparency committee
---